Tech Company Financing Transactions
GlycoMimetics Funding Round
On 10/20/2009, GlycoMimetics secured $38 million in Series A investment from Alliance Technology Ventures, Anthem Capital and Genzyme Ventures.
Transaction Overview
Company Name
Announced On
10/20/2009
Transaction Type
Venture Equity
Amount
$38,000,000
Round
Series A
Investors
Genzyme Ventures (Rachel King)
New Enterprise Associates (James Barrett)
Proceeds Purpose
The new investment will be used to fund a Phase 2 trial of GlycoMimetics' lead drug candidate GMI-1070 in vaso-occlusive crisis of sickle cell disease. The company also intends to use proceeds to fund a Phase 2 study of GMI-1070 in a second clinical indication.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
9708 Medical Center Dr. 250
Gaithersburg, MD 20850
USA
Gaithersburg, MD 20850
USA
Phone
Website
Email Address
Overview
GlycoMimetics is a clinical-stage biotechnology company utilizing novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rachel King
Chief Financial Officer
Brian Hahn
Chief Medical Officer
Helen Thackray
Chief Scientific Officer
John Magnani
VP - Bus. Development
Armand Girard
VP - Operations
Henry Flanner
Browse more venture capital transactions:
Prev: 10/20/2009: Currensee venture capital transaction
Next: 10/20/2009: Jive Software venture capital transaction
Share this article
Where The Data Comes From
We do our best to record tech company VC transactions. VC investment data records reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs